Equibles does not estimate personal net worth.
Get an email with a short summary when Summit Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get SMMT alertsSummit Therapeutics Inc. reported in an 8-K filed October 16, 2023 that Dave Gancarz was appointed Chief Business & Strategy Officer, effective October 16, 2023. Dave Gancarz has spoken on 3 earnings calls across 1 company, most recently for Summit Therapeutics Inc. on July 23, 2026. Summit Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Summit Therapeutics Inc. includes Glyn Edwards (CEO), Mahkam Zanganeh (CEO, COO and Board Member), Robert Duggan (CEO and Board Member) and 7 others.
“Today, Summit announces that, effective immediately, the following elevated appointments have been made: Dave Gancarz as Chief Business & Strategy Officer”
“On today's call, we will provide an update on our second quarter 2026 financial results and operational progress. This afternoon's press release is available on our website, www.smmttx.com. Our form 10Q was also filed today and is available on our website and via the SEC's website.”
“We issued a press release on Friday morning regarding the expansion of our Phase III clinical development programs, unveiling the global Phase III study in first-line colorectal cancer.”
“Two press releases were issued earlier this morning and are available on the homepage of our website. Our Form 10-K was also filed earlier this morning and is available on our website.”
Source not stated
Biotechnology · Healthcare
